Cinzia Traboni

TL;DR: It is discovered that the hepatitis C virus (HCV) envelope glycoprotein E2 binds to human hepatoma cell lines independently of the previously proposed HCV receptor CD81, and the receptor responsible for E2 binding to human hepatic cells is identified as the human scavenger receptor class B type I (SR‐BI).

TL;DR: It is demonstrated that vaccines developed with adenoviral vectors can induce broad and sustained immune responses to HCV in humans and open the way for studies of prophylactic and therapeutic vaccines for HCV.

TL;DR: A first-in-human trial of a prime-boost vaccine strategy for HCV, with durable, broad, sustained, and balanced T cell responses, characteristic of those associated with viral control, paving the way for the first efficacy studies of a prophylactic HCV vaccine.

TL;DR: It is shown that rare serotypes of human adenoviruses, which should not be neutralized in most humans, are far less potent as vaccine vectors than Ad5 in mice and nonhuman primates, casting doubt on their potential efficacy in humans.

TL;DR: An open-label, dose escalation, phase 1 clinical trial in 42 healthy adults in which four different combinations of prime/boost vaccinations were investigated for safety and immunogenicity, including both intramuscular and intranasal administration of the adenovirus-vectored vaccine.